These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2412053)

  • 41. Is there alpha-adrenergic blockade and/or serotonergic blockade during chronic ketanserin treatment?
    Ball SG; Robertson JI
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S120-2. PubMed ID: 2412031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiovascular effects of ketanserin in closed-chest anesthetized dogs.
    van de Water A; Wouters L; Xhonneux R; Reneman S
    Arch Int Pharmacodyn Ther; 1985 Jun; 275(2):267-78. PubMed ID: 3161481
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The influence of ketanserin on hemostasis in vitro.
    Bergqvist D; Arvidsson S; Haglund U; Hedner U; Lindblad B
    Thromb Res; 1986 Jul; 43(2):237-41. PubMed ID: 2943051
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension.
    Stott DJ; Saniabadi AR; Hosie J; Lowe GD; Ball SG
    Eur J Clin Pharmacol; 1988; 35(2):123-9. PubMed ID: 3142775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ketanserin in the acute management of severe hypertension.
    Murphy BF; Whitworth JA; Kincaid-Smith P
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S168-71. PubMed ID: 2412044
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Placebo-controlled, double-blind, two-centre trial of ketanserin in intermittent claudication.
    Bounameaux H; Holditch T; Hellemans H; Berent A; Verhaeghe R
    Lancet; 1985 Dec; 2(8467):1268-71. PubMed ID: 2866336
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Continuous inhibition of the platelet S2-serotonergic receptors during the long term administration of ketanserin.
    Vermylen J; Arnout J; Deckmyn H; Xhonneux B; De Clerck F
    Thromb Res; 1986 Jun; 42(5):721-3. PubMed ID: 2940729
    [No Abstract]   [Full Text] [Related]  

  • 48. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
    Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of ketanserin on phenylephrine-dependent changes in splanchnic hemodynamics and systemic blood pressure in healthy subjects.
    Gasic S; Eichler HG; Korn A
    J Cardiovasc Pharmacol; 1985; 7(2):219-23. PubMed ID: 2581071
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular profile and hypotensive mechanism of ketanserin in the rabbit.
    Bolt GR; Saxena PR
    Hypertension; 1985; 7(4):499-506. PubMed ID: 2861161
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative effects of ketanserin, a novel serotonergic receptor antagonist, on 5HT-induced shape change and 5HT uptake in rat and human platelets.
    Lampugnani MG; de Gaetano G
    Biochem Pharmacol; 1982 Sep; 31(18):3000-2. PubMed ID: 7138588
    [No Abstract]   [Full Text] [Related]  

  • 52. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency.
    Wenting GJ; Woittiez AJ; Man in't Veld AJ; Schalekamp MA
    Hypertension; 1984; 6(1):100-9. PubMed ID: 6319278
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of serotonin antagonists on blood pressure in mineralocorticoid hypertensive sheep.
    Mecca TE; Mitchell J; Bohr DF; Webb RC
    J Cardiovasc Pharmacol; 1985; 7(4):660-5. PubMed ID: 2410705
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serotonin metabolism and age-related effects of antihypertensive therapy with ketanserin.
    Amstein R; Fetkovska N; Ferracin F; Pletscher A; Bühler FR
    Drugs; 1988; 36 Suppl 1():61-6. PubMed ID: 2467792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effects of intravenous nicardipine on blood pressure, hemorheology platelet function in arterial hypertension. Dose-effect relations].
    Zannad F; Voisin P; Sadoul N; Marchal C; Donetti C; Stoltz JF; Gilgenkrantz JM
    Arch Mal Coeur Vaiss; 1987 Jun; 80(6):844-50. PubMed ID: 3116984
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serotonin and haemorrheology.
    Dormandy JA
    Int J Cardiol; 1987 Feb; 14(2):213-9. PubMed ID: 3818137
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Age, platelet serotonin kinetics and 5HT2-receptor blockade in essential hypertension.
    Amstein R; Fetkovska N; Bühler FR
    J Hum Hypertens; 1990 Aug; 4(4):441-4. PubMed ID: 2258891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs.
    Novo S; Alaimo G; Abrignani MG; Giordano U; Avellone G; Pinto A; Adamo L; Cutietta A; Indovina A; Strano A
    Int J Clin Pharmacol Res; 1986; 6(3):199-211. PubMed ID: 2943685
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension.
    Hedner T; Persson B
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):317S-323S. PubMed ID: 3046635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.